MX388054B - Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. - Google Patents

Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Info

Publication number
MX388054B
MX388054B MX2018013347A MX2018013347A MX388054B MX 388054 B MX388054 B MX 388054B MX 2018013347 A MX2018013347 A MX 2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A MX 388054 B MX388054 B MX 388054B
Authority
MX
Mexico
Prior art keywords
hair loss
janus
jak
deuterated
inhibitors
Prior art date
Application number
MX2018013347A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013347A (es
Inventor
Amanda T Wagner
Colleen E Hamilton
James V Cassella
Hehn Jana Von
Philip B Graham
Vinita Uttamsingh
Virginia Braman
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX388054(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Publication of MX2018013347A publication Critical patent/MX2018013347A/es
Publication of MX388054B publication Critical patent/MX388054B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018013347A 2016-05-04 2017-05-04 Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. MX388054B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US201762492758P 2017-05-01 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors

Publications (2)

Publication Number Publication Date
MX2018013347A MX2018013347A (es) 2019-09-02
MX388054B true MX388054B (es) 2025-03-19

Family

ID=60203616

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2018013347A MX388054B (es) 2016-05-04 2017-05-04 Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002325A MX2023002325A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002323A MX2023002323A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002321A MX2023002321A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021014175A MX2021014175A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002324A MX2023002324A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Family Applications After (5)

Application Number Title Priority Date Filing Date
MX2023002325A MX2023002325A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002323A MX2023002323A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002321A MX2023002321A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021014175A MX2021014175A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002324A MX2023002324A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Country Status (21)

Country Link
US (3) US10561659B2 (enExample)
EP (2) EP4424367A3 (enExample)
JP (3) JP7145080B2 (enExample)
KR (3) KR20190003711A (enExample)
CN (3) CN122440641A (enExample)
AU (3) AU2017261286B2 (enExample)
BR (1) BR112018072339A2 (enExample)
CA (1) CA3022519A1 (enExample)
DK (1) DK3452039T3 (enExample)
ES (1) ES2988629T3 (enExample)
FI (1) FI3452039T3 (enExample)
HR (1) HRP20241345T1 (enExample)
HU (1) HUE068643T2 (enExample)
LT (1) LT3452039T (enExample)
MX (6) MX388054B (enExample)
PL (1) PL3452039T3 (enExample)
PT (1) PT3452039T (enExample)
RS (1) RS66006B1 (enExample)
SI (1) SI3452039T1 (enExample)
SM (1) SMT202400389T1 (enExample)
WO (1) WO2017192905A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561659B2 (en) * 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3921318A1 (en) * 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) * 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US12643902B2 (en) 2020-08-12 2026-06-02 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched substituted pyrrolo[2,3-d]pyrimidines
US20220213105A1 (en) 2020-08-12 2022-07-07 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
US20230390292A1 (en) * 2020-10-28 2023-12-07 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
AU2022328282A1 (en) 2021-08-12 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
US20260027120A1 (en) * 2024-07-25 2026-01-29 Sun Pharmaceutical Industries, Inc. Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
PT2635299T (pt) * 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
CA2879400A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
KR102242077B1 (ko) * 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
MX2016010213A (es) * 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
EP4424367A3 (en) 2024-11-13
JP2019516684A (ja) 2019-06-20
JP7586868B2 (ja) 2024-11-19
EP3452039A4 (en) 2019-12-25
AU2017261286B2 (en) 2023-03-23
SI3452039T1 (sl) 2024-12-31
JP2025026895A (ja) 2025-02-26
MX2023002325A (es) 2023-03-22
EP4424367A2 (en) 2024-09-04
AU2017261286A1 (en) 2018-11-22
AU2023201112B2 (en) 2025-05-08
JP7145080B2 (ja) 2022-09-30
US20200222408A1 (en) 2020-07-16
CN122440641A (zh) 2026-07-24
KR20190003711A (ko) 2019-01-09
US10561659B2 (en) 2020-02-18
US20240423986A1 (en) 2024-12-26
ES2988629T3 (es) 2024-11-21
HUE068643T2 (hu) 2025-01-28
KR102810262B1 (ko) 2025-05-19
PL3452039T3 (pl) 2024-11-18
EP3452039B1 (en) 2024-07-03
CA3022519A1 (en) 2017-11-09
LT3452039T (lt) 2024-10-25
BR112018072339A2 (pt) 2019-02-19
MX2023002323A (es) 2023-03-22
FI3452039T3 (fi) 2024-10-02
JP2022171838A (ja) 2022-11-11
DK3452039T3 (da) 2024-10-07
MX2021014175A (es) 2022-01-04
AU2025213576A1 (en) 2025-08-21
MX2018013347A (es) 2019-09-02
MX2023002321A (es) 2023-03-22
HRP20241345T1 (hr) 2024-12-20
AU2023201112A1 (en) 2023-03-30
PT3452039T (pt) 2024-10-07
KR20250070139A (ko) 2025-05-20
KR20230086814A (ko) 2023-06-15
MX2023002324A (es) 2023-03-22
CN109069493A (zh) 2018-12-21
WO2017192905A1 (en) 2017-11-09
CN121868312A (zh) 2026-04-17
SMT202400389T1 (it) 2024-11-15
US20190160068A1 (en) 2019-05-30
US12076323B2 (en) 2024-09-03
EP3452039A1 (en) 2019-03-13
RS66006B1 (sr) 2024-10-31

Similar Documents

Publication Publication Date Title
MX2023002321A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
EA202190630A1 (ru) Способы комбинированной терапии
EA202191177A1 (ru) 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
EA202091708A1 (ru) Ингибиторы днк-пк
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
MX388470B (es) Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados.
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MX2021013602A (es) Inhibidores de jak.
WO2016109217A3 (en) Btk inhibitors
JOP20230090A1 (ar) نظم لعلاج الاضطرابات المتعلقة بفقدان الشعر باستخدام مثبطات jak معالجة بالديوتريوم
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
JOP20170148A1 (ar) مثبطات Wnt لعلاج التليف
BR112022005608A2 (pt) Inibidores de jak
EA202190751A1 (ru) Способы лечения миелопролиферативных расстройств
ZA202106519B (en) Caspase inhibitors and methods of use thereof
JOP20240130A1 (ar) مثبطات تفاعل منين-mll
MX2022001702A (es) Inhibidores de jak.
EA201792676A1 (ru) Ингибиторы jak1
EA201892360A1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak